secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-08-26T20:15:42+00:00
Accession:  0001213900-26-093979
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics receives Nasdaq delisting notice for equity shortfall
-------------------------------------------------------------------------

- On Aug 21, 2026, Nasdaq notified Jasper it fails $2.5M stockholders' equity requirement under Rule 5550(b)(1).
- Company has 45 days (until Oct 5, 2026) to submit a compliance plan to regain compliance.
- Plans to seek stockholder approval to convert Non-Voting Convertible Preferred Stock to boost equity.
- If plan accepted, Nasdaq may grant up to 180-day extension; otherwise hearing process available.
- No immediate effect on listing; common stock continues trading on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026093979/0001213900-26-093979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026093979/ea0303509-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-093979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer